Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis

Best, Lawrence; Leung, JT; Freeman, Suzanne C.; Sutton, Alex J.; Cooper, Nicola J.; Milne, EJ; Cowlin, Maxine; Payne, Anna; Walshaw, Dana; Thorburn, Douglas; Pavlov, Chavdar S; Davidson, Brian R; Tsochatzis, Emmanuel; Williams, Norman; Gurusamy, Kurinchi Selvan

doi:10.1002/14651858.cd013203.pub2

Cited by 12 publications

(10 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…36 Our findings are consistent with the previous Cochrane review of effectiveness of rATG on preventing AR among recipients with rATG compared with those with basiliximab. 38 We further observed that the effect did not differ among older (≥65 y) and younger (18-64) recipients.…”

Section: Discussionmentioning

confidence: 55%

The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age

Ahn

Bae

Chu

et al. 2021

Transplantation Direct

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 55%

The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age

Ahn

Bae

Chu

et al. 2021

Transplantation Direct

View full text Add to dashboard Cite

show abstract

“…Data on patient outcomes related to induction IS choice are lacking. The previously cited low-quality data does not show significant differences in outcomes based on induction regimen (2,3).…”

Section: Discussionmentioning

confidence: 77%

“…The overall clinical impact of this variation in pediatric practice is unknown. In adults, previous systematic reviews have found minimal differences between T-cell depleting antibody (TDA) induction and non-TDA with many limitations based on low-quality evidence (2,3). Regarding the impact of costs on clinical outcomes, a 2016 examination of differences in utilization among pediatric liver transplant centers concluded that there was no correlation between higher overall costs and mortality, graft failure, or lower rates of readmission (4).…”

mentioning

confidence: 99%

Association Between Perioperative Costs and Induction Immunosuppression in Pediatric Liver Transplant Recipients

Ewing

Farnan²,

Squires³

2023

Journal of Pediatric Gastroenterology &Amp; Nutrition

View full text Add to dashboard Cite

Objectives:The objectives of this study was to describe variation in induction regimen, identify predictors of induction immunosuppression (IS) choice, and examine the impact of induction IS regimen on length of stay (LOS) and total perioperative costs in pediatric liver transplant recipients. Methods: We analyzed liver transplant utilization data in the Pediatric Health Information System database. Patients were divided into 3 induction IS groups: (1) steroids only, (2) T-cell depleting antibody (TDA), and (3) non-TDA. We identified predictors of induction IS regimen and examined associations between each outcome and choice of induction IS. Results: We analyzed 4905 liver transplant recipients (50% female, 80% under age 13 years, 42% non-Hispanic White). Most patients (3162, 64%) received steroids only induction, and about twice as many patients received a non-TDA regimen (1093, 22%) versus a TDA regimen (650, 13%). Median total perioperative costs were highest for the TDA group

show abstract

“…The network meta-analysis is mainly used to compare the clinical efficacy of three or more interventions 9 . In this study, four types of combined Chinese medicine with azithromycin for treatment of MPC were analyzed.…”

Section: Discussionmentioning

confidence: 99%

Effects of four types of chinese medicines as concomitant drugs with azithromycin for the treatment of mycoplasma pneumonia in children in China: a network meta-analysis

Jin

Chen

2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE:The purpose of this study was to evaluate the efficacy of the use of four concomitant Chinese medicines with azithromycin in the treatment of mycoplasma pneumonia in children (MPC) by using network meta-analysis (NMA) and ranking them according to their performances.METHODS: There were a total of 130 randomly controlled trials of four different concomitant Chinese medicines with azithromycin for the treatment of MPC in many databases, and an NMA was conducted in them by using Stata (version 13.0) software to evaluate the odds ratio (OR) and sequence of the different combinations. The included studies were divided into two groups: control group (azithromycin alone) and observation group (one of four azithromycin combinations).RESULTS: A total of 13119 cases were included in this study, and the results showed that the pooled OR and 95% confidence interval (CI) of MPC improvement compared with azithromycin alone were 4.76 (3.18-7.14) for azithromycin and Reduning, 5.66 (4.50-7.12) for azithromycin and Tanreqing,) for azithromycin and Xiyanping, and 4.58 (3.59-5.83) for azithromycin and Yanhuning, respectively. This study shows the significant efficacy of Chinese concomitant drug. The combination of azithromycin with Tanreqing is the best candidate of concomitant drug in terms of clinical efficacy. Its surface under the cumulative ranking (SUCRA) score was 85.5, while the SUCRA score for the azithromycin and Yanhuning combination was the worst, which is 48.4. CONCLUSIONS:The combination of azithromycin with Tanreqing is the most promising group among four combinations for the treatment of MPC.

show abstract

Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis

Abstract: Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis (Review)

Cited by 12 publications

References 122 publications

The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age

The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age

Association Between Perioperative Costs and Induction Immunosuppression in Pediatric Liver Transplant Recipients

Effects of four types of chinese medicines as concomitant drugs with azithromycin for the treatment of mycoplasma pneumonia in children in China: a network meta-analysis

Contact Info

Product

Resources

About